Inactive Instrument

Antibe Therapeutics Inc.

Equities

ATE

CA0370255097

Biotechnology & Medical Research

Antibe Therapeutics Inc. Announces Retirement of Dr. John L. Wallace from the Board of Directors

February 15, 2023 at 07:00 am

Antibe Therapeutics Inc. announced that its founder, Dr. John L. Wallace, has decided to retire from the Board of Directors. Dr. Wallace will remain a corporate Vice Chair, enabling the company to continue to benefit from his wisdom and expertise.

Latest news about Antibe Therapeutics Inc.

Antibe Therapeutics Inc. Announces Board Resignations	04-24	CI
Antibe Therapeutics Seeks Extension of Stay of Proceedings	04-19	MT
Antibe Therapeutics Says the TSX Reviewing a Potential Delisting of its Shares	04-16	MT
Antibe Therapeutics Brief: Announcing TSX Delisting Review	04-16	MT
Antibe Therapeutics Brief: Says To File an Application for an Initial Order Under Companies' Creditors Arrangement Act	04-09	MT
Antibe Therapeutics Inc. Announces Board Resignations	04-09	CI
Toronto Stocks Edge Lower; Ballard Power Rises on Fuel-Cell Order	04-01	DJ
Antibe Therapeutics Shares Down on Clinical Hold on Otenaproxesul by U.S. Regulator	04-01	DJ
Antibe Therapeutics Brief: Down More Than 50% After Announcing FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	04-01	MT
Antibe Therapeutics Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	04-01	MT
Antibe Therapeutics Brief: Announcing FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	04-01	MT
Antibe Therapeutics Inc. Announces FDA Clinical Hold on Otenaproxesul	04-01	CI
Antibe Therapeutics Inc. Announces Formation of Executive Committee	04-01	CI
Antibe Therapeutics Brief: Says to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting	03-20	MT
Antibe Therapeutics Brief: To Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting Tomorrow	03-07	MT
Antibe Therapeutics Announces Unfavorable Decision in Arbitration With Nuance Pharma	03-04	MT
Antibe Reported Q3 2024 Interim Financial and Operating Results	02-14	MT
Antibe Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Antibe Extending Early Warrant Exercise Incentive Program	02-01	MT
Antibe Therapeutics Announced Early Warrant Exercise Incentive Program	12-29	MT
Antibe Therapeutics Up 4% After Announcing Amendment To Warrant Extension, Price Changes	12-12	MT
Antibe Therapeutics Reports Q3 2023 Net and Comprehensive Loss of $5 Million	11-13	MT
Antibe Therapeutics Brief: For Quarter ended September 30, 2023, Net Loss and Comprehensive Loss totaled $5.0 million ($0.10 per share)	11-13	MT
Antibe Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-13	CI
Antibe Therapeutics Inc. Reports PK Results of First Clinical Study of Otenaproxesul?s New Formulation	11-09	CI

Chart Antibe Therapeutics Inc.

Duration

Period

More charts

Company Profile

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Companyâs pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

Sector

Biotechnology & Medical Research

Calendar

2024-06-26 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	123B
REGENERON PHARMACEUTICALS, INC.	+14.53%	107B
BIONTECH SE	-2.88%	24.01B
ARGENX SE	+2.18%	22.59B
GENMAB A/S	-10.09%	18.16B
WUXI APPTEC CO., LTD.	-41.04%	16.84B
BEIGENE, LTD.	-11.83%	16.23B
NEUROCRINE BIOSCIENCES, INC.	+1.46%	13.43B
SAREPTA THERAPEUTICS, INC.	+24.22%	11.32B

Bio Therapeutic Drugs